Market Cap: $4.74B
CA
CRISPR Therapeutics AG
CRSP
NASDAQ (NASDAQ Global Market)USD
Market Cap: $4.74B
CRISPR Therapeutics AG ( CRSP ) is carving out a critical space in the rapidly evolving biotech landscape, propelled by its innovative gene-editing technologies. With the launch of its groundbreaking…
CRISPR Therapeutics AG (Ticker: CRSP) makes strategic corporate moves to enhance its growth potential in the competitive biopharmaceutical landscape. The company is proactively adapting to market dyna…
CRISPR Therapeutics AG (Ticker: CRSP) is making significant strides in the gene editing sector, primarily through its innovative product Casgevy. Recent reports indicate that the company is witnessing…
CRISPR Therapeutics AG (Ticker: CRSP) showcases a pivotal moment in its financial journey with the release of its results for the first quarter of 2026. Highlighting a revenue of $1.46 million, the co…
CRISPR Therapeutics AG (Ticker: CRSP) is making significant strides in its growth strategy, as recently articulated by CEO Sam Kulkarni. The company is moving into a 'second phase' following the succe…
CRISPR Therapeutics AG is actively expanding its clinical pipeline with significant advancements in gene editing technologies, notably through its lead CAR-T program, zugo-cel. The company is making n…
CRISPR Therapeutics Reinforces Financial Strategy with Convertible Notes Offer CRISPR Therapeutics AG has outlined a significant move to enhance its financial footing by announcing plans to raise $350…
FDA Leadership Transition Signals Implications for Biopharmaceutical Innovation The recent announcement from FDA Commissioner Marty Makary about the impending departure of Dr. Vinay Prasad from his ro…
FDA Leadership Transition Heights Regulatory Uncertainty for Biopharmaceuticals The recent announcement by FDA Commissioner Marty Makary regarding Dr. Vinay Prasad's upcoming departure from his positi…
CRISPR Therapeutics Advances Gene Editing Technology Amidst Growing Pipeline CRISPR Therapeutics AG is making significant strides in the biopharmaceutical sector, particularly concerning its pioneerin…
Oncolytics Biotech Advances Immuno-Oncology Strategies with Promising Developments In a competitive landscape where innovation is crucial, Oncolytics Biotech Inc. is making significant strides in the…
CRISPR Therapeutics Advances in Gene Therapy Potential CRISPR Therapeutics AG emerges as a pioneering force in the biopharmaceutical landscape, particularly in the field of gene editing therapies. The…
Synthego's Strategic Expansion into Diagnostic Reagents: Pioneering Next-Gen Solutions Synthego, a prominent player in CRISPR technologies, announces its foray into the molecular and clinical diagnost…
Synthego Expands into Diagnostics with Innovative Reagent Line Synthego, a frontrunner in CRISPR technology, announces its strategic entry into the molecular and clinical diagnostic reagents market, e…
Synthego Enters Diagnostic Reagents Market, Enhancing CRISPR Applications Synthego, a prominent player in the realm of CRISPR technologies, announces its strategic foray into the molecular and clinica…
HUTCHMED Advances Autoimmune Treatment with Promising Phase 3 Trial Results HUTCHMED (China) Limited recently unveils significant findings from the Phase 3 registration segment of its ESLIM-02 clinica…
HUTCHMED's Clinical Breakthrough: A New Hope for Autoimmune Hemolytic Anemia HUTCHMED (China) Limited has recently made significant strides in the biopharmaceutical sector with the announcement of pro…
HUTCHMED's Breakthrough in Autoimmune Hemolytic Anemia Treatment HUTCHMED (China) Limited recently announces significant findings from the Phase 3 registration segment of the ESLIM-02 clinical trial f…
Genomic Innovations Set to Transform Healthcare: ARK Invest's Strategic Shift Cathie Wood, CEO of ARK Invest, is actively reshaping her investment strategy in anticipation of a transformative era for…
ARK Invest's Strategic Embrace of Genomic Technologies: A Precursor to Transformation in Healthcare Cathie Wood, CEO of ARK Invest, is actively reshaping her investment strategy in anticipation of a t…
### A Strategic Shift Towards Genomic Innovation: ARK Invest's Vision for 2026 In a notable strategic pivot, Cathie Wood, CEO of ARK Invest, expresses a strong belief in the transformative power of ge…
CRISPR Therapeutics Advances CAR T Therapy with Promising Updates on Zugocaptagene Geleucel CRISPR Therapeutics AG announces significant progress in its investigational allogeneic CAR T therapy, zugoc…
CRISPR Therapeutics Advances Innovative CAR T Therapy for Autoimmune Diseases and Hematologic Malignancies CRISPR Therapeutics AG is making notable strides in the development of its investigational al…
CRISPR Therapeutics Advances CAR T-Cell Therapy with Zugocaptagene Geleucel CRISPR Therapeutics AG is making significant strides in the development of its investigational allogeneic CAR T therapy, zug…
Revolutionizing Precision Medicine: The Role of Gene Therapy in Longevity The precision medicine sector is experiencing rapid growth, anticipated to soar from $119 billion in 2025 to a staggering $471…